Vol. 6, Issue 1 (2017)
Spirometry changes in stable COPD patients treated with roflumilast
Iryna Savelikhina, Mykola Ostrovskyy, Oleksandr Varunkiv, Mariana Kulynych-Miskiv and Kseniia Ostrovska
COPD is a progressive condition involving chronic inflammation and parenchymal destruction with resulting airflow limitation. COPD is associated with worsening airflow limitation over time and increased frequency of COPD exacerbations, leading to increased mortality and morbidity worldwide. The effects of COPD extend beyond the lungs, as multiple comorbidities may occur with COPD, including cardiovascular disease, diabetes mellitus, osteoporosis, depression, and pneumonia.
Roflumilast is a selective inhibitor of the enzyme phosphodiesterase-4 that targets the systemic inflammation associated with COPD. Roflumilast has a variety of anti-inflammatory effects including decreasing inflammatory mediators and the expression of cell surface markers and inhibition of apoptosis.
How to cite this article:
Iryna Savelikhina, Mykola Ostrovskyy, Oleksandr Varunkiv, Mariana Kulynych-Miskiv and Kseniia Ostrovska. Spirometry changes in stable COPD patients treated with roflumilast. The Pharma Innovation Journal. 2017; 6(1): 07-09.